Canaccord Genuity Maintains Buy on Neuronetics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 62.3%

Neg 62.3% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $7 to $3.